CHEK1 and medulloblastoma: For instance, Prexacertib (LY2606368), a novel Chk inhibitor with preference for Chk1, is being tested at present in clinical trials for medulloblastoma together with Gemcitabine as a DNA damage inducer (NCT04023669).